AU746633B2 - Methods of enhancing functioning of the upper gastrointestinal tract - Google Patents

Methods of enhancing functioning of the upper gastrointestinal tract Download PDF

Info

Publication number
AU746633B2
AU746633B2 AU75163/98A AU7516398A AU746633B2 AU 746633 B2 AU746633 B2 AU 746633B2 AU 75163/98 A AU75163/98 A AU 75163/98A AU 7516398 A AU7516398 A AU 7516398A AU 746633 B2 AU746633 B2 AU 746633B2
Authority
AU
Australia
Prior art keywords
glp
gastrointestinal tract
upper gastrointestinal
analog
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU75163/98A
Other languages
English (en)
Other versions
AU7516398A (en
Inventor
Daniel J. Drucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1149336 Ontario Inc
Original Assignee
1149336 Ontario Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9715481.9A external-priority patent/GB9715481D0/en
Priority claimed from US09/059,504 external-priority patent/US6051557A/en
Application filed by 1149336 Ontario Inc filed Critical 1149336 Ontario Inc
Publication of AU7516398A publication Critical patent/AU7516398A/en
Application granted granted Critical
Publication of AU746633B2 publication Critical patent/AU746633B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU75163/98A 1997-05-16 1998-05-15 Methods of enhancing functioning of the upper gastrointestinal tract Ceased AU746633B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US4675497P 1997-05-16 1997-05-16
US60/046754 1997-05-16
GBGB9715481.9A GB9715481D0 (en) 1997-07-23 1997-07-23 Methods of enhancing functioning of the upper gastrointestinal tract
GB9715481 1997-07-23
US09/059,504 US6051557A (en) 1997-05-16 1998-04-13 Methods of enhancing functioning of the upper gastrointestinal tract
US09/059504 1998-04-13
PCT/CA1998/000497 WO1998052600A1 (en) 1997-05-16 1998-05-15 Methods of enhancing functioning of the upper gastrointestinal tract

Publications (2)

Publication Number Publication Date
AU7516398A AU7516398A (en) 1998-12-11
AU746633B2 true AU746633B2 (en) 2002-05-02

Family

ID=27268946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75163/98A Ceased AU746633B2 (en) 1997-05-16 1998-05-15 Methods of enhancing functioning of the upper gastrointestinal tract

Country Status (13)

Country Link
EP (1) EP0981362B1 (enExample)
JP (2) JP4699576B2 (enExample)
CN (1) CN1264307B (enExample)
AT (1) ATE253375T1 (enExample)
AU (1) AU746633B2 (enExample)
BR (1) BR9808804A (enExample)
CA (1) CA2289652C (enExample)
DE (1) DE69819488T2 (enExample)
DK (1) DK0981362T3 (enExample)
ES (1) ES2210756T3 (enExample)
MX (1) MXPA99010523A (enExample)
PT (1) PT981362E (enExample)
WO (1) WO1998052600A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253375T1 (de) * 1997-05-16 2003-11-15 Ontario Inc 1149336 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
GB9905416D0 (en) * 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
RU2164349C1 (ru) * 1999-07-27 2001-03-20 Нижегородская государственная медицинская академия Способ определения стоматологического статуса
WO2001041779A2 (en) * 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
PT1326630E (pt) * 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
DK1809318T3 (da) 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
DE602006020123D1 (de) † 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
AU2007319066B2 (en) * 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
JP5908478B2 (ja) * 2010-08-30 2016-04-26 エヌピーエス ファーマシューティカルズ インコーポレイテッドＮｐｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US20180200301A1 (en) * 2015-05-21 2018-07-19 Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
CN108273038B (zh) * 2018-03-16 2019-03-19 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN110226566A (zh) * 2019-07-12 2019-09-13 南京中医药大学 一种放射性口腔黏膜炎动物模型的造模方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP2275438A1 (en) * 1996-04-12 2011-01-19 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
ES2181054T3 (es) * 1996-12-06 2003-02-16 Amgen Inc Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento.
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
ATE253375T1 (de) * 1997-05-16 2003-11-15 Ontario Inc 1149336 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes

Also Published As

Publication number Publication date
ATE253375T1 (de) 2003-11-15
WO1998052600A9 (en) 2000-03-09
DE69819488D1 (de) 2003-12-11
CA2289652A1 (en) 1998-11-26
DE69819488T2 (de) 2004-08-26
ES2210756T3 (es) 2004-07-01
MXPA99010523A (es) 2004-09-01
AU7516398A (en) 1998-12-11
EP0981362A1 (en) 2000-03-01
BR9808804A (pt) 2001-09-18
JP2002502369A (ja) 2002-01-22
EP0981362B1 (en) 2003-11-05
CN1264307B (zh) 2013-10-30
HK1030160A1 (en) 2001-04-27
CN1264307A (zh) 2000-08-23
PT981362E (pt) 2004-03-31
JP2009280598A (ja) 2009-12-03
WO1998052600A1 (en) 1998-11-26
JP4699576B2 (ja) 2011-06-15
CA2289652C (en) 2012-02-28
DK0981362T3 (da) 2004-03-15

Similar Documents

Publication Publication Date Title
US6051557A (en) Methods of enhancing functioning of the upper gastrointestinal tract
US8278273B2 (en) Methods of enhancing functioning of the large intestine
CA2289652C (en) Methods of enhancing functioning of the upper gastrointestinal tract
CA2274596C (en) Compositions and methods for enhancing intestinal function
EP1988100B1 (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
US9592273B2 (en) Treatment of short bowel syndrome patients with colon-in-continuity
WO1999058144A1 (en) Methods of enhancing functioning of the large intestine
HK1030160B (en) Methods of enhancing functioning of the upper gastrointestinal tract
HK1107026B (en) Treatment of short bowel syndrome patients with colon-in-continuity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)